{"analyses":[{"ciLowerLimit":"0.886","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.417","estimateComment":"Cabazitaxel 25 mg/m\\^2 vs Docetaxel 75 mg/m\\^2","groupDescription":"Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"1.121"},{"ciLowerLimit":"0.798","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.288","estimateComment":"Cabazitaxel 20 mg/m\\^2 vs Docetaxel 75 mg/m\\^2","groupDescription":"Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"1.014"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.24","upperLimit":"22.44","value":"19.0"},{"groupId":"OG001","lowerLimit":"15.21","upperLimit":"24.61","value":"19.2"},{"groupId":"OG002","lowerLimit":"14.59","upperLimit":"20.50","value":"17.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"391"},{"groupId":"OG001","value":"389"},{"groupId":"OG002","value":"388"}],"units":"Participants"}],"description":"SRE free survival was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SRE or death due to any cause, whichever was earlier. SRE were assessed by clinical evaluation. Occurrence of SRE was defined as: pathological fracture(s) and/or spinal cord compression; need for bone irradiation, including radioisotopes or bone surgery; and change of antineoplastic therapy (including introduction of bisphosphonates or denosumab in the setting of increased pain) to treat bone pain. Analysis was performed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel (TXT) 75 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG000","title":"Docetaxel 75 mg/m^2"},{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG001","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG002","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on ITT population which included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline until occurrence of first SRE or death (maximum duration: 51 months)","title":"Skeletal Related Events (SRE) Free Survival","type":"SECONDARY","unitOfMeasure":"months"}